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ASSOCIATIONS BETWEEN BASELINE LOW DENSITY LIPOPROTEIN
CHOLESTEROL (LDL-C) LEVELS AND TREATMENT INITIATION OF
SELECTED STATINS IN A MANAGED CARE POPULATION
Tunceli K1, Sajjan S2, Ramey DR3
1Merck & Co., Inc., Whitehouse Station, NJ, USA, 2Merck & Co., Inc., West Point, PA, USA, 
3Merck & Co., Inc., Upper Gwynedd, PA, USA
OBJECTIVES: Individuals who are not at ATP III (Adult Treatment Panel III) LDL-C 
goal are recommended to take statins along with lifestyle modiﬁ cations. Different lipid 
lowering therapies (LLT) vary in their average LDL-C efﬁ cacy. The goal of this retro-
spective, observational study is to examine the association between initiation of 
selected statins and LDL-C levels before the prescribing in a cohort of CHD/CHD risk
equivalent individuals. METHODS: Using a large managed care administrative claims 
database, we identiﬁ ed individuals with at least one prescription for simvastatin plus
ezetimibe ﬁ xed dose combination (simvastatin/ezetimibe), simvastatin, atorvastatin, or 
rosuvastatin between January 01, 2005 and December 31, 2006. Patients were 
excluded if they met any of the following criteria: use of any LLT during the 6 months
prior (baseline) to the index (ﬁ rst prescription) date; prescription ﬁ lls for more than 
one LLT on the index date; no lab value; or at LDL-C goal (100 mg/dL) at baseline 
based on ATP III cholesterol guidelines. Three logistic regression models adjusting 
for age and gender were developed to examine the association between being q50% 
away from LDL-C goal at baseline and simvastatin/ezetimibe initiation (N  2246)
relative to simvastatin (N  2615), atorvastatin (N  5703), and rosuvastatin (N 
1446) monotherapy. RESULTS: A total of 13,651 eligible patients were treatment
naïve and not at LDL-C goal at baseline. Compared to individuals who were 50% 
away from the ATP III goal, patients who were 50% or more away from goal were
1.8 (95% CI  1.6–2.1), 1.4 (1.2–1.5), and 1.1 (0.9–1.2) times more likely to be pre-
scribed simvastatin/ezetimibe rather than simvastatin, atorvastatin, and rosuvastatin
monotherapy, respectively. CONCLUSIONS: The positive association between being
q50% away from LDL-C goal and initiation of simvastatin/ezetimibe vs. simvastatin 
or atorvastatin suggests that physicians were choosing simvastatin/ezetimibe because 
of the anticipated higher efﬁ cacy with this combination than the statin monotherapy 
studied.
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OBJECTIVES: To analyse the utilisation of anti-hypertensive drugs within Slovakia 
between 1998 and 2007 and to assess the economic consequences of anti-hypertensive 
medications. METHODS: For 1998–2007, the data about consumption of drugs for 
cardiovascular disease were collected in accordance with ATC/DDD measurement
unit. This analysis focused on the situation in anti-hypertensive medication in more 
detail. Data of wholesalers, who are legally obliged provide this information to the 
Slovak Institute for Drug Control, was used for the analysis. RESULTS: A signiﬁ cant
increase in the medication cardiovascular disease in 1998 (258.55), in 2003 (380.15) 
and in 2007 (510.73) in term of DDD/1000/day can be seen from this analysis.
The results show that the consumption (in terms of DDD/1000/day) of B-blockers
was in 1998 (31.21), in 2003 (41.40) and in 2007 (47.82), Agents acting on the 
rennin-angiotensin system (in 1998 (39.16), in 2003 (84.88) and in 2007 (139.61),
Ca-blockers (in 1998 (33.47) in 2003 (57.54) and in 2007 (77.18), Diuretics (in 1998
(27.17), in 2003 (32.56) and in 2007 (39.25), Peripheral vasodilators (in 1998 (21.14), 
in 2003 (20.64) and in 2007 (16.01), Serum lipid reducing agents in 1998 (7.34),
in 2003 (27.21) and in 2007 (63.34). In ﬁ nancial terms, the consumption of B-
blockers in 1998 (€8,728,000) and 2007 (€14,622,000), Agents acting on the rennin-
angiotensin system in 1998 (€15,615,000) and 2007 (€55,094,000), Ca-blockers
in 1998 (€14,496,000) and 2007 (€21,624,000), Diuretics in 1998 (€1,909,000) 
and 2007 (€4,560,000), Peripheral vasodilators in 1998 (€5,460,000) and in 2007
(€5,252,000), Serum lipid reducing agents in 1998 (€9,609,000€) and 2007 
(€26,279,000€) can be seen from this study. CONCLUSIONS: Usage of generic drugs
for the treatment of cardiovascular diseases brought about a dramatic increase in drug 
consumption and the ﬁ nancial expenditures for health insurance funds have remained
under control.
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ADHERENCE TO MAINTENANCE MEDICATIONS BY DAYS SUPPLY AND
DISTRIBUTION CHANNEL
Liberman JN1, Wang Y1, Hutchins DS2
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OBJECTIVES: To compare medication adherence among patients exclusively receiving
30-day or 90-day supplies of maintenance medications from a single distribution
channel. METHODS: Patients (n  289,337) receiving maintenance medications with
only a 30 or 90 day supply and from one distribution channel (retail/mail) for all their 
prescriptions were selected from a 10% random sample of members (n  22,577,122) 
with continuous pharmacy beneﬁ ts eligibility from July 1, 2006 through December 
31, 2007. Medication Possession Ratios (MPRs) were calculated for ACEs, ARBs, 
calcium channel blockers (CCBs), sulfonylureas, metformin, and statins for these
patients; from their ﬁ rst pharmacy claim between January 1 and March 30, 2007 
through December 31, 2007. Patient MPRs were aggregated by their 30/90-day sup-
plies, retail/mail channel, and whether they were initiators (no claims from July 1, 
2006 to December 31, 2006) or continuers. RESULTS: Overall, MPRs ranged from
85% (metformin) to 88% (ACEs and CCBs) for individuals ﬁ lling 90-day and 69%
(metformin) to 76% (CCBs) for individuals ﬁ lling 30-day supplies, with 90-day aver-
aging 19.4% higher than 30-day. MPRs for 90-day mail were systematically higher
than 90-day retail (average MPR: 82.4% vs. 80.9%), and member costs were less for 
90-day mail in ﬁ ve therapeutic classes (average cost difference: $10.16 per prescrip-
tion). Initiator MPR differences were more pronounced, ranging from 72% (statins
and metformin) to 76% (ACEs) for 90-day and 52% (sulfonylureas and metformin) 
to 56% (statins) for 30-day supplies. Initiators who exclusively received 90-day mail 
prescriptions also beneﬁ ted from systematically higher MPR scores (5 to 7 percentage
points, on average) than those exclusively receiving 90-day retail prescriptions. CON-
CLUSIONS: Extended days supply (i.e., 90-day) for maintenance medications sub-
stantially increased adherence measures, overall and among those initiating therapy. 
However, lower adherence among patients receiving 90-day retail prescriptions rela-
tive to those receiving 90-day mail, may be attributable to the higher out-of-pocket
costs from prescriptions for current 90-day retail programs.
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A LONGITUDINAL ANALYSIS OF ANGIOTENSIN RECEPTOR BLOCKER
(ARB) PRESCRIBING PATTERNS UNDER A PRIOR-AUTHORIZATION
REQUIREMENT
Kahan NR, Waitman DA, Vardy DA
Leumit Health Fund, Tel-Aviv, Israel
OBJECTIVES: Since the introduction of ARBs into the Israeli market in 2001, the 
Leumit Health Fund has enforced a prior authorization (PA) requirement for these
relatively expensive drugs. We hypothesized that the trends in requests by physicians
for these drugs would reﬂ ect the variance in the intensity of marketing campaigns 
for the different products over time. The objective of this study was to evaluate 
the trends in the patterns of requests for the ARBs available in Israel between 2001 
and 2008, and to correlate the ﬁ ndings with available information describing the 
marketing campaigns that were concomitantly launched. METHODS: Data on all 
requests for PA approval for ARBs was retrieved for the relevant study period. The 
proportion of requests for individual drugs during each quarter of the eight years 
studied was calculated. The longitudinal trends in physician patterns for requests 
were analyzed to identify trends surrounding launch dates of new products, introduc-
tion of generic equivalents, and expiration of international marketing licenses.
RESULTS: Initially, four different products were introduced into the market with 
49% of requests for losartan, 19% for both valsartan and candesartan, and 13%
for irbesartan. During the 3 month period in 2007 prior to the introduction of 
generic losartan when the drug was no longer being detailed, the proportion of 
requests for all drugs was: valsartan 58%, losartan 24%, candesartan 17%, and 
olmesartan 1%. Similar trends were identiﬁ ed for other drugs. CONCLUSIONS:
Analysis of variance in the proportion of PA requests for drugs within a pharmacologi-
cal category is a feasible method for monitoring physician prescribing behavior which 
may be strongly inﬂ uenced by aggressive marketing. Under a PA constraint this 
method is preferable since dispensing data poorly reﬂ ects MD preferences due to the 
barrier created by PA.
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PATTERN OF CLOPIDOGREL USE IN PERCUTANEOUS CORONARY
INTERVENTION PATIENTS
Yu HT1, Dean BB1, Bae JP2, Fiske S1, Xiong Y1, Emons MF1
1Cerner LifeSciences, Beverly Hills, CA, USA, 2Eli Lilly and Company, Indianapolis, IN, USA
OBJECTIVES: Clopidogrel at a 300 mg loading dose is approved in acute coronary 
syndrome (ACS) patients who undergo percutaneous coronary intervention (PCI).
Studies suggest clopidogrel generates more beneﬁ t if it is given early. Giving a loading 
dose of 600 mg has been suggested to achieve a more rapid inhibition of antiplatelet 
aggregation. This study examined real world clopidogrel use pattern among patients 
who undergo PCI. METHODS: HealthFacts (Cerner Corp) is electronic medical 
record data with time-stamped information. Study cohort was 6,253 PCI patients who 
received a minimum 300 mg loading of clopidogrel between 24 hours before and up
to 6 hours after PCI either with or without ACS diagnoses from 40 interventional
cardiology centers between January 2006 and March 2008 (Elective PCI n  3,922, 
ACS-PCI n  2,331, of which 972 had UN/NSTEMI). High dose was deﬁ ned as 
q600 mg. Early treatment was reported at 6 hours for 300 mg and 1 hour for 600 mg
prior to PCI. RESULTS: Slightly over half(56.9%) the patients received 600 mg or 
higher loading dose, and 32.0% received 300 mg. The remaining 11.1% received a 
dose in between. Loading was given as bolus in 75.4%, two doses in 21.5%, and q3 
in 3.1%. Among UA/NSTEMI subgroup, 25.8% initiated ﬁ rst does at 6 hours, and 
additional 9.6% started their high dose q1 hour prior to PCI. A majority (68.3% of 
PCI, and 56.4% in UA/NSTEMI), however, received clopidogrel during or after PCI. 
CONCLUSIONS: There exist some uncertainties about optimal dosing of clopidogrel
in patients who undergo PCI. While 600 mg was frequently chosen, early treatment 
with clopidogrel was relatively rare in this sample. Further observation will be required 
to monitor guideline adherence and outcomes.
